Arvinas Inc

NASDAQ:ARVN

7.95

+0.05 (+0.63%)

4:12:45 PM EDT: $7.95 0.00 (0.00%)

Market Cap (Intraday)	583.94M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$34.42 Million
Adjusted EPS	-$0.94

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Arvinas Inc Stock, NASDAQ:ARVN

5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511

United States of America

Phone: +1.203.535.1456

Number of Employees: 430

http://www.arvinas.com

Description

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.